Metastatic progression defines the final stages of tumor evolution and underlies the majority
of cancer-related deaths. The heterogeneity in disseminated tumor cell populations capable …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) causes massive medical
problems because of late diagnosis and limited responsiveness to standard …

Pancreatic cancer is detected late in the disease process and has an extremely poor
prognosis. A blood-based biomarker that can enable early detection of disease, monitor …

Pancreatic ductal adenocarcinoma (PDAC) is the most frequent pancreatic cancer type,
characterized by a dismal prognosis due to late diagnosis, frequent metastases, and limited …

Background Early diagnosis of pancreatic ductal adenocarcinoma (PDAC) is difficult due to
the lack of effective screening tests. CA199, the standard biomarker for PDAC management …

Pancreatic cancer is the fourth leading cause of cancer-related death in the USA and
Europe; early symptoms and screenings are lacking, and it is usually diagnosed late with a …

Pancreatic cancer is a public health problem because of its increasing incidence, the
absence of early diagnostic tools, and its aggressiveness. Despite recent progress in …

Purpose: We have previously identified tissue methylated DNA markers (MDMs) associated
with pancreatic ductal adenocarcinoma (PDAC). In this case–control study, we aimed to …

Pancreatic cancer is one of the main causes of cancer-related deaths worldwide. It is
asymptomatic at an early stage, and most diagnosis occurs when the disease is already at a …

Background It has been shown that circulating tumor cells in peripheral blood can be used
to predict survival in patients with breast, prostate and other epithelial tumors. In the present …